Hepatocyte transplantation for inherited metabolic diseases of the liver

Journal of Internal Medicine

Volumn 272, Issue 3, 2012, Pages 201-223

  Jorns, C ^a   Ellis, E C ^a   Nowak, G ^a   Fischler, B ^b   Nemeth, A ^b   Strom, S C ^c   Ericzon, B G ^a  

^a Division of Transplantation Surgery   (Sweden)

^b Department of Clinical Science Intervention and Technology ^*  (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

1 antitrypsin deficiency; Experimental; Hepatology; Liver; Surgery; Transplantation immunology

Indexed keywords

BLOOD CLOTTING FACTOR; LIVER ENZYME; LIVER PROTEIN;

ACUTE INTERMITTENT PORPHYRIA; CELL ISOLATION; CELL LOSS; CELL TRANSPLANTATION; CRIGLER NAJJAR SYNDROME; CRYOPRESERVATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC DISORDER; GLYCOGEN STORAGE DISEASE TYPE 1; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANTILE REFSUM DISEASE; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; MAPLE SYRUP URINE DISEASE; METABOLIC DISORDER; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW; TYROSINEMIA; UREA CYCLE DISORDER; WILSON DISEASE;

ADAPTIVE IMMUNITY; ANIMALS; CELL AGING; CELL CULTURE TECHNIQUES; CELL TRANSPLANTATION; CRYOPRESERVATION; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; LIVER DISEASES; METABOLISM, INBORN ERRORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 84865089184     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02574.x     Document Type: Review

References (143)

1. Hughes RD, Mitry RR, Dhawan A et al. One liver, three recipients: Segment IV from split-liver procedures as a source of hepatocytes for cell transplantation. Transplantation 2004; 77: 1614-6.
2. Hughes RD. Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation. Liver Transpl 2006; 12: 713-7.
3. Strom SC, Dorko K, Thompson MT, Pisarov LA, Nussler AK. Ilots de Langerhans et hepatocytes: vers une utilisation therapeutique. Nature Pub Group 1998; 1: 195-205.
4. Berry MN, Friend DS. High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 1969; 43: 506-20.
5. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13: 29-83.
6. Gramignoli R, Green ML, Tahan V et al. Development and application of purified tissue dissociation enzyme mixtures for human hepatocyte isolation. Cell Transplant 2011; [Epub ahead of print].
7. Kawahara T, Toso C, Douglas DN et al. Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl 2010; 16: 974-82.
8. Sagias FG, Mitry RR, Hughes RD et al. N-acetylcysteine improves the viability of human hepatocytes isolated from severely steatotic donor liver tissue. Cell Transplant 2010; 19: 1487-92.
9. Stephenne X, Najimi M, Ngoc DK et al. Cryopreservation of human hepatocytes alters the mitochondrial respiratory chain complex 1. Cell Transplant 2007; 16: 409-19.
10. Gramignoli R, Marongiu F, Tahan V et al. Isolation and evaluation of human hepatocytes for cell-based therapy. Dig Liver Dis 2011; 43: S96.
11. Donato MT, Lahoz A, Montero S et al. Functional assessment of the quality of human hepatocyte preparations for cell transplantation. Cell Transplant 2008; 17: 1211-9.
12. Janny S, Bert F, Dondero F et al. Microbiological findings of culture-positive preservation fluid in liver transplantation. Transpl Infect Dis 2011; 13: 9-14.
13. Mattner F, Kola A, Fischer S et al. Impact of bacterial and fungal donor organ contamination in lung, heart-lung, heart and liver transplantation. Infection 2008; 36: 207-12.
14. Lehec SC, Hughes RD, Mitry RR et al. Experience of microbiological screening of human hepatocytes for clinical transplantation. Cell Transplant 2009; 18: 941-7.
15. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001; 13: 343-68.
16. Bonora-Centelles A, Donato MT, Lahoz A et al. Functional characterization of hepatocytes for cell transplantation: customized cell preparation for each receptor. Cell Transplant 2010; 19: 21-8.
17. Darwish AA, Sokal E, Stephenne X, Najimi M, de Goyet JV, Reding R. Permanent access to the portal system for cellular transplantation using an implantable port device. Liver Transpl 2004; 10: 1213-5.
18. Meyburg J, Alexandrova K, Barthold M et al. Liver cell transplantation: basic investigations for safe application in infants and small children. Cell Transplant 2009; 18: 777-86.
19. Baccarani U, Adani GL, Sanna A et al. Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient. Transpl Int 2005; 18: 750-4.
20. Fox IJ, Chowdhury JR, Kaufman SS et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338: 1422-6.
21. Nagata H, Ito M, Shirota C, Edge A, McCowan TC, Fox IJ. Route of hepatocyte delivery affects hepatocyte engraftment in the spleen. Transplantation 2003; 76: 732-4.
22. Strom SC, Fisher RA, Thompson MT et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63: 559-69.
23. Habibullah CM, Syed IH, Qamar A, Taher-Uz Z. Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58: 951-2.
24. Pilichos C, Perrea D, Demonakou M, Preza A, Donta I. Management of carbon tetrachloride-induced acute liver injury in rats by syngeneic hepatocyte transplantation in spleen and peritoneal cavity. World J Gastroenterol 2004; 10: 2099-102.
25. Abrahamse SL, van Runnard Heimel P, Hartman RJ, Chamuleau RA, van Gulik TM. Induction of necrosis and DNA fragmentation during hypothermic preservation of hepatocytes in UW, HTK, and Celsior solutions. Cell Transplant 2003; 12: 59-68.
26. Pless G, Sauer IM, Rauen U. Improvement of the cold storage of isolated human hepatocytes. Cell Transplant 2012; 21: 23-37.
27. Smets FN, Chen Y, Wang LJ, Soriano HE. Loss of cell anchorage triggers apoptosis (anoikis) in primary mouse hepatocytes. Mol Genet Metab 2002; 75: 344-52.
28. Stephenne X, Najimi M, Sokal EM. Hepatocyte cryopreservation: is it time to change the strategy? World J Gastroenterol 2010; 16: 1-14.
29. Terry C, Dhawan A, Mitry RR, Hughes RD. Cryopreservation of isolated human hepatocytes for transplantation: state of the art. Cryobiology 2006; 53: 149-59.
30. Gomez-Lechon MJ, Lahoz A, Jimenez N, Vicente Castell J, Donato MT. Cryopreservation of rat, dog and human hepatocytes: influence of preculture and cryoprotectants on recovery, cytochrome P450 activities and induction upon thawing. Xenobiotica 2006; 36: 457-72.
31. Terry C, Hughes RD, Mitry RR, Lehec SC, Dhawan A. Cryopreservation-induced nonattachment of human hepatocytes: role of adhesion molecules. Cell Transplant 2007; 16: 639-47.
32. Stephenne X. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 2005; 5: 2058-61.
33. Meyburg J. One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation 2009; 87: 636-41.
34. Dhawan A, Mitry RR, Hughes RD et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812-4.
35. Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006; 29: 431-5.
36. Terry C, Dhawan A, Mitry RR, Lehec SC, Hughes RD. Optimization of the cryopreservation and thawing protocol for human hepatocytes for use in cell transplantation. Liver Transpl 2010; 16: 229-37.
37. Miyamoto Y, Suzuki S, Nomura K, Enosawa S. Improvement of hepatocyte viability after cryopreservation by supplementation of long-chain oligosaccharide in the freezing medium in rats and humans. Cell Transplant 2006; 15: 911-9.
38. Katenz E, Vondran FW, Schwartlander R et al. Cryopreservation of primary human hepatocytes: the benefit of trehalose as an additional cryoprotective agent. Liver Transpl 2007; 13: 38-45.
39. Luebke-Wheeler JL, Nedredal G, Yee L, Amiot BP, Nyberg SL. E-cadherin protects primary hepatocyte spheroids from cell death by a caspase-independent mechanism. Cell Transplant 2009; 18: 1281-7.
40. Terry C, Mitry RR, Lehec SC et al. The effects of cryopreservation on human hepatocytes obtained from different sources of liver tissue. Cell Transplant 2005; 14: 585-94.
41. Gupta S. Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. Hepatology 1999; 29: 509-19.
42. Gupta S, Rajvanshi P, Lee CD. Integration of transplanted hepatocytes into host liver plates demonstrated with dipeptidyl peptidase IV-deficient rats. Proc Natl Acad Sci U S A 1995; 92: 5860-4.
43. Koenig S, Stoesser C, Krause P, Becker H, Markus PM. Liver repopulation after hepatocellular transplantation: integration and interaction of transplanted hepatocytes in the host. Cell Transplant 2005; 14: 31-40.
44. Bilir BM. Hepatocyte transplantation in acute liver failure. Liver Transpl 2000; 6: 32-40.
45. Oertel M, Menthena A, Dabeva MD, Shafritz DA. Cell competition leads to a high level of normal liver reconstitution by transplanted fetal liver stem/progenitor cells. Gastroenterology 2006; 130: 507-20; quiz 90.
46. Koenig S, Krause P, Schmidt TK et al. Irradiation as preparative regimen for hepatocyte transplantation causes prolonged cell cycle block. Int J Radiat Biol 2008; 84: 285-98.
47. Malhi H, Gorla GR, Irani AN, Annamaneni P, Gupta S. Cell transplantation after oxidative hepatic preconditioning with radiation and ischemia-reperfusion leads to extensive liver repopulation. Proc Natl Acad Sci U S A 2002; 99: 13114-9.
48. Laconi E, Oren R, Mukhopadhyay DK et al. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am J Pathol 1998; 153: 319-29.
49. -/- mice. Nat Biotechnol 2007; 25: 903-10.
50. Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr 2006; 165: 306-19.
51. Groth CG, Arborgh B, Bjorken C, Eriksson G, Lundgren G. Hepatocellular transplantation in glucuronyltransferase-deficient rat Sven Kir 1974; 31: 42.
52. Groth CG, Arborgh B, Bjorken C, Sundberg B, Lundgren G. Correction of hyperbilirubinemia in the glucuronyltransferase-deficient rat by intraportal hepatocyte transplantation. Transplant Proc 1977; 9: 313-6.
53. Matas AJ. Hepatocellular transplantation for metabolic deficiencies: decrease of plasma bilirubin in Gunn rats. Science 1976; 192: 892-4.
54. Horslen SP, Fox IJ. Hepatocyte transplantation. Transplantation 2004; 77: 1481-6.
55. Dhawan A, Puppi J, Hughes RD, Mitry RR. Human hepatocyte transplantation: current experience and future challenges. Nat Rev Gastroenterol Hepatol 2010; 7: 288-98.
56. Ambrosino G. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant 2005; 14: 151-7.
57. Lysy PA. Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives. World J Gastroenterol 2008; 14: 3464-70.
58. Allen KJ, Mifsud NA, Williamson R, Bertolino P, Hardikar W. Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transpl 2008; 14: 688-94.
59. Darwish AA, McKiernan P, Chardot C. Paediatric liver transplantation for metabolic disorders. Part 1: Liver-based metabolic disorders without liver lesions. Clin Res Hepatol Gastroenterol 2011; 35: 194-203.
60. Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol 2002; 7: 27-35.
61. Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58.
62. Ban K, Sugiyama N, Sugiyama K et al. A pediatric patient with classical citrullinemia who underwent living-related partial liver transplantation. Transplantation 2001; 71: 1495-7.
63. Michel JL, Rabier D, Rambaud C et al. [Intrasplenic transplantation of hepatocytes in spf-ash mice with congenital ornithine transcarbamylase deficiency]. Chirurgie 1993; 119: 666-71.
64. Stephenne X. Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology 2006; 130: 1317-23.
65. Meyburg J, Burlina A, Nuoffer JM et al. Quantification of therapeutic success after liver cell transplantation (LCT) for neonatal urea cycle disorders (UCD). Mol Genet Metab 2009; 98: 10.
66. Eguchi S, Rozga J, Lebow LT et al. Treatment of hypercholesterolemia in the Watanabe rabbit using allogeneic hepatocellular transplantation under a regeneration stimulus. Transplantation 1996; 62: 588-93.
67. Gunsalus JR, Brady DA, Coulter SM, Gray BM, Edge AS. Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation. Nat Med 1997; 3: 48-53.
68. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR, Wilson JM. Long-term improvement of hypercholesterolemia after exvivo gene-therapy in ldlr-deficient rabbits. Science 1991; 254: 1802-5.
69. Grossman M. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-54.
70. Grossman M, Raper SE, Kozarsky K et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-41.
71. Chou JY, Jun HS, Mansfield BC. Glycogen storage disease type I and G6Pase-beta deficiency: etiology and therapy. Nat Rev Endocrinol 2010; 6: 676-88.
72. Specht A, Fiske L, Erger K et al. Glycogen storage disease type Ia in canines: a model for human metabolic and genetic liver disease. J Biomed Biotechnol 2011; 2011: 646257.
73. Muraca M. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359: 317-8.
74. Lee KW. Hepatocyte transplantation for glycogen storage disease type Ib. Cell Transplant 2007; 16: 629-37.
75. Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW. Peroxisome biogenesis disorders. Biochim Biophys Acta 2006; 1763: 1733-48.
76. Van Maldergem L, Moser AB, Vincent MF et al. Orthotopic liver transplantation from a living-related donor in an infant with a peroxisome biogenesis defect of the infantile Refsum disease type. J Inherit Metab Dis 2005; 28: 593-600.
77. Sokal EM. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 2003; 76: 735-8.
78. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; 9: CD003429.
79. Lambing A, Kachalsky E, Kuriakose P. Liver transplantation in the haemophilia patient. Haemophilia 2011; 17: e981-4.
80. Ohashi K, Waugh JM, Dake MD et al. Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132-40.
81. Tatsumi K, Ohashi K, Shima M, Nakajima Y, Okano T, Yoshioka A. Therapeutic effects of hepatocyte transplantation on hemophilia B. Transplantation 2008; 86: 167-70.
82. Arnell H, Fischler B, Bergdahl S, Schnell PO, Jacobsson H, Nemeth A. Hepatobiliary scintigraphy during cholestatic and noncholestatic periods in patients with progressive familial intrahepatic cholestasis after partial external biliary diversion.J Pediatr Surg 2011; 46: 467-72.
83. De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RP. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119: 1720-30.
84. Quaglia A, Lehec SC, Hughes RD et al. Liver after hepatocyte transplantation for liver-based metabolic disorders in children. Cell Transplant 2008; 17: 1403-14.
85. Loeber JG. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis 2007; 30: 430-8.
86. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010; 376: 1417-27.
87. Vajro P, Strisciuglio P, Houssin D et al. Correction of phenylketonuria after liver transplantation in a child with cirrhosis. N Engl J Med 1993; 329: 363.
88. Hamman K, Clark H, Montini E et al. Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Mol Ther 2005; 12: 337-44.
89. Hamman KJ, Winn SR, Harding CO. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU). Mol Genet Metab 2011; 104: 235-40.
90. Smets FN, Stephenne X, Debray G et al. Hepatocyte Transplantation Transforms Severe Phenylketonuria to Mild Hyperphenylalaninemia. Gastroenterology 2011; 140: 967.
91. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet 2007; 369: 397-408.
92. Yoshida Y, Tokusashi Y, Lee GH, Ogawa K. Intrahepatic transplantation of normal hepatocytes prevents Wilson's disease in Long-Evans Cinnamon rats. Gastroenterology 1996; 111: 1654-60.
93. Malhi H, Joseph B, Schilsky ML, Gupta S. Development of cell therapy strategies to overcome copper toxicity in the LEC rat model of Wilson disease. Regen Med 2008; 3: 165-73.
94. Bissig KD, Wieland SF, Tran P et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120: 924-30.
95. Skvorak KJ. Animal models of maple syrup urine disease. J Inherit Metab Dis 2009; 32: 229-46.
96. Skvorak KJ, Hager EJ, Arning E et al. Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD). Biochim Biophys Acta 2009; 1792: 1004-10.
97. Skvorak KJ, Paul HS, Dorko K et al. Hepatocyte transplantation improves phenotype and extends survival in a murine model of intermediate maple syrup urine disease. Mol Ther 2009; 17: 1266-73.
98. Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG. Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int 2010; 23: e18-21.
99. Nilsson B, Ekdahl KN, Korsgren O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr Opin Organ Transplant 2011; 16: 620-6.
100. Stephenne X. Tissue factor-dependent procoagulant activity of isolated human hepatocytes: relevance to liver cell transplantation. Liver Transpl 2007; 13: 599-606.
101. Gustafson EK, Elgue G, Hughes RD et al. The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation 2011; 91: 632-8.
102. Schmidt P, Magnusson C, Lundgren T, Korsgren O, Nilsson B. Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor. Transplantation 2008; 86: 1523-30.
103. Joseph B. Kupffer cells participate in early clearance of syngeneic hepatocytes transplanted in the rat liver. Gastroenterology 2002; 123: 1677-85.
104. Krohn N. Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells. Gastroenterology 2009; 136: 1806-17.
105. Bumgardner GL, Gao D, Li J, Baskin JH, Heininger M, Orosz CG. Rejection responses to allogeneic hepatocytes by reconstituted SCID mice, CD4, KO, and CD8 KO mice. Transplantation 2000; 70: 1771-80.
106. Fishman JA. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transpl 2011; 17(Suppl 3): S34-7.
107. Korsgren O, Nilsson B, Berne C et al. Current status of clinical islet transplantation. Transplantation 2005; 79: 1289-93.
108. Fisher RA. Defining hepatocellular chimerism in a liver failure patient bridged with hepatocyte infusion. Transplantation 2000; 69: 303-7.
109. Mas VR, Maluf DG, Thompson M, Ferreira-Gonzalez A, Fisher RA. Engraftment measurement in human liver tissue after liver cell transplantation by short tandem repeats analysis. Cell Transplant 2004; 13: 231-6.
110. Bohnen NI, Charron M, Reyes J et al. Use of indium-111-labeled hepatocytes to determine the biodistribution of transplanted hepatocytes through portal vein infusion. Clin Nucl Med 2000; 25: 447-50.
111. Puppi J, Modo M. Use of magnetic resonance imaging contrast agents to detect transplanted liver cells. Top Magn Reson Imaging 2009; 20: 113-20.
112. Donato MT, Lahoz A, Jimenez N et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 2006; 34: 1556-62.
113. Ericzon BG, Larsson M, Wilczek HE. Domino liver transplantation: risks and benefits. Transplant Proc 2008; 40: 1130-1.
114. Wilczek HE, Larsson M, Yamamoto S, Ericzon BG. Domino liver transplantation. J Hepatobiliary Pancreat Surg 2008; 15: 139-48.
115. Navarro-Alvarez N, Soto-Gutierrez A, Kobayashi N. Stem cell research and therapy for liver disease. Curr Stem Cell Res Ther 2009; 4: 141-6.
116. Haridass D, Narain N, Ott M. Hepatocyte transplantation: waiting for stem cells. Curr Opin Organ Transplant 2008; 13: 627-32.
117. Bonavita AG, Quaresma K, Cotta-de-Almeida V, Pinto MA, Saraiva RM, Alves LA. Hepatocyte xenotransplantation for treating liver disease. Xenotransplantation 2010; 17: 181-7.
118. Ekser B, Ezzelarab M, Hara H et al. Clinical xenotransplantation: the next medical revolution? Lancet 2012; 379: 672-83.
119. Witek RP, Fisher SH, Petersen BE. Monocrotaline, an alternative to retrorsine-based hepatocyte transplantation in rodents. Cell Transplant 2005; 14: 41-7.
120. Puppi J, Strom SC, Hughes RD et al. Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London. Cell Transplant 2012; 21: 1-10.
121. Abdalla EK. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010; 102: 960-7.
122. Dagher I. Efficient hepatocyte engraftment and long-term transgene expression after reversible portal embolization in nonhuman primates. Hepatology 2009; 49: 950-9.
123. Lainas P. Liver regeneration and recanalization time course following reversible portal vein embolization. J Hepatol 2008; 49: 354-62.
124. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 2010; 176: 2-13.
125. Yamanouchi K. Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. Hepatology 2009; 49: 258-67.
126. Krause P, Wolff HA, Rave-Frank M et al. Fractionated external beam radiotherapy as a suitable preparative regimen for hepatocyte transplantation after partial hepatectomy. Int J Radiat Oncol Biol Phys 2011; 80: 1214-9.
127. Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 2011; 21: 256-63.
128. Wiederkehr JC, Kondos GT, Pollak R. Hepatocyte transplantation for the low-density-lipoprotein receptor deficient state - a study in the watanabe rabbit. Transplantation 1990; 50: 466-71.
129. Attaran M, Schneider A, Grote C et al. Regional and transient ischemia/reperfusion injury in the liver improves therapeutic efficacy of allogeneic intraportal hepatocyte transplantation in low-density lipoprotein receptor deficient Watanabe rabbits. J Hepatol 2004; 41: 837-44.
130. Wilson JM, Chowdhury NR, Grossman M et al. Temporary amelioration of hyperlipidemia in low-density-lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes. Proc Natl Acad Sci U S A 1990; 87: 8437-41.
131. Irani AN, Malhi H, Slehria S et al. Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans Cinnamon rats modeling Wilson's disease. Mol Ther 2001; 3: 302-9.
132. Allen KJ, Cheah DM, Wright PF et al. Liver cell transplantation leads to repopulation and functional correction in a mouse model of Wilson's disease. J Gastroenterol Hepatol 2004; 19: 1283-90.
133. Jiang JL, Salido EC, Guha C et al. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1. Transplantation 2008; 85: 1253-60.
134. Kocken JM, Rinkes I, Bijma AM et al. Correction of an inborn error of metabolism by intraportal hepatocyte transplantation in a dog model. Transplantation 1996; 62: 358-64.
135. Holzman MD, Rozga J, Neuzil DF, Griffin D, Moscioni AD, Demetriou AA. Selective intraportal hepatocyte transplantation in analbuminemic and gunn-rats. Transplantation 1993; 55: 1213-9.
136. Rozga J, Holzman M, Moscioni AD, Fujioka H, Morsiani E, Demetriou AA. Repeated intraportal hepatocyte transplantation in analbuminemic rats. Cell Transplant 1995; 4: 237-43.
137. Moscioni AD, Rozga J, Chen S, Naim A, Scott HS, Demetriou AA. Long-term correction of albumin levels in the Nagase analbuminemic rat: repopulation of the liver by transplanted normal hepatocytes under a regeneration response. Cell Transplant 1996; 5: 499-503.
138. Overturf K, Al-Dhalimy M, Tanguay R et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996; 12: 266-73.
139. Wahlin S, Yin Z, Nowak G, Ellis E, Ericzon BG, Harper P. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Br J Dermatol 2011; 164: 1144.
140. Strom SC. Transplantation of human hepatocytes. Transplant Proc 1997; 29: 2103-6.
141. Horslen SP. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111: 1262-7.
142. Puppi J. Hepatocyte transplantation followed by auxiliary liver transplantation[mdash]a novel treatment for ornithine transcarbamylase deficiency. Am J Transplant 2008; 8: 452-7.
143. Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006; 82: 441-9.